Edition:
India

Merck KGaA (MRCG.DE)

MRCG.DE on Xetra

114.60EUR
4:38pm IST
Change (% chg)

€-1.55 (-1.33%)
Prev Close
€116.15
Open
€114.20
Day's High
€114.95
Day's Low
€111.80
Volume
377,056
Avg. Vol
500,434
52-wk High
€125.95
52-wk Low
€85.84

Latest Key Developments (Source: Significant Developments)

Bavencio Significantly Improved Overall Survival In Patients With Locally Advanced Or Metastatic Urothelial Carcinoma
Monday, 6 Jan 2020 

Jan 6 (Reuters) - Pfizer Inc ::BAVENCIO SIGNIFICANTLY IMPROVED OVERALL SURVIVAL IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA.EMD SERONO - AT PLANNED INTERIM ANALYSIS, PHASE III JAVELIN BLADDER 100 STUDY MET PRIMARY ENDPOINT.EMD SERONO - SAFETY PROFILE FOR BAVENCIO IN TRIAL WAS CONSISTENT WITH THAT IN JAVELIN MONOTHERAPY CLINICAL DEVELOPMENT PROGRAM.  Full Article

Physiomics Says Currently Trading In Line With Market Expectations
Friday, 20 Dec 2019 

Dec 20 (Reuters) - Physiomics PLC ::PHYSIOMICS PLC - MERCK CONTRACTS.PHYSIOMICS - EXPECTS FURTHER CONTRACTS SIGNED IN 2020, BUT TOTAL EXPECTED VALUE OF CONTRACTS ACROSS WHOLE CALENDAR YEAR NOT YET KNOWN WITH CERTAINTY.PHYSIOMICS PLC - COMPANY BELIEVES THAT IT IS CURRENTLY TRADING IN LINE WITH MARKET EXPECTATIONS.PHYSIOMICS- IF COMPLETED ACCORDING TO SCHEDULE, REVENUE PER MONTH FOR MERCK CONTRACTS DURING FY ENDING 30 JUNE 2020 WILL BE ABOUT SAME AS PREVIOUS FY.PHYSIOMICS PLC - CLIENT MERCK KGAA COMMITTED TO AN INITIAL TRANCHE OF PROJECTS FOR 2020 WITH AN AGGREGATE VALUE OF £250,000.  Full Article

Merck KGaA Signs License Agreement Providing Promega Corp.
Thursday, 19 Dec 2019 

Dec 19 (Reuters) - Merck KGaA ::MERCK KGAA - ANNOUNCED THAT IT HAS SIGNED A LICENSE AGREEMENT PROVIDING PROMEGA CORP..  Full Article

Neurable Raises $6 Million In Series A Funding
Wednesday, 18 Dec 2019 

Dec 18 (Reuters) - Neurable : :NEUROTECHNOLOGY CO NEURABLE RAISES $6 MILLION IN SERIES A TO BUILD AN "EVERYDAY" BRAIN-COMPUTER INTERFACE.NEURABLE - FINANCING LED BY M VENTURES, WITH PARTICIPATION OF INNOSPARK VENTURES, LOUP VENTURES & POINT JUDITH CAPITAL.  Full Article

Merck To Designate Orphan Drug For Investigational Therapy Tepotinib
Wednesday, 20 Nov 2019 

Nov 20 (Reuters) - MERCK KGAA ::ANNOUNCES ORPHAN DRUG DESIGNATION FOR INVESTIGATIONAL THERAPY TEPOTINIB IN PATIENTS WITH NSCLC HARBORING MET GENE ALTERATIONS.JAPANESE MINISTRY OF HEALTH, LABOUR AND WELFARE GRANTS ORPHAN DRUG DESIGNATION FOR DISEASES THAT AFFECT FEWER THAN 50,000 PATIENTS IN JAPAN, AND FOR WHICH SIGNIFICANT UNMET MEDICAL NEED EXISTS.  Full Article

Merck KGaA Needs 2 Yrs To Reduce Net To Have Greater Flexibility -CFO
Thursday, 14 Nov 2019 

Nov 14 (Reuters) - Merck KGaA CFO::WE WOULD NEED ABOUT 2 YRS TO REDUCE NET DEBT TO LEVEL THAT ALLOWS US GREATER FLEXIBILITY.  Full Article

Merck Signs License Agreement With Evotec
Tuesday, 12 Nov 2019 

Nov 12 (Reuters) - MERCK KGAA ::IT HAS SIGNED A LICENSE AGREEMENT PROVIDING EVOTEC SE ACCESS TO MERCK’S FOUNDATIONAL CRISPR INTELLECTUAL PROPERTY.  Full Article

Merck KGaA’S Javelin Gastric 100 Trial Misses Primary Endpoints
Friday, 8 Nov 2019 

Nov 8 (Reuters) - Merck KGaA ::MERCK AND PFIZER PROVIDE UPDATE ON PHASE III JAVELIN GASTRIC 100 TRIAL.WHILE STUDY SHOWED CLINICAL ACTIVITY FOR AVELUMAB, IT DID NOT MEET PRIMARY ENDPOINTS OF SUPERIOR OVERALL SURVIVAL.  Full Article

European Commission Approves Bavencio Plus Axitinib Combination
Monday, 28 Oct 2019 

Oct 28 (Reuters) - Merck KGaA ::EUROPEAN COMMISSION APPROVES BAVENCIO® (AVELUMAB) PLUS AXITINIB COMBINATION FOR FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA.MERCK KGAA - APPROVAL WAS BASED ON POSITIVE INTERIM RESULTS FROM PHASE III JAVELIN RENAL 101 STUDY.MERCK KGAA - COMBINATION REGIMEN APPROVED ACROSS ALL IMDC PROGNOSTIC RISK GROUPS AND IRRESPECTIVE OF PD-L1 EXPRESSION.MERCK KGAA - ADDITIONALLY, WITH APPROVAL, POSOLOGY SECTION OF SUMMARY OF PRODUCT CHARACTERISTICS FOR BAVENCIO HAS BEEN UPDATED.  Full Article

Merck KGaA Says Chinese Regulator Approves Cancer Treatment Erbitux
Friday, 27 Sep 2019 

Sept 27 (Reuters) - Merck KGaA ::APPROVAL IS FOR ERBITUX® IN COMBINATION WITH FOLFOX OR FOLFIRI FOR FIRST-LINE TREATMENT, OR IN COMBINATION WITH IRINOTECAN IN PATIENTS WHO ARE REFRACTORY TO IRINOTECAN-BASED CHEMOTHERAPY.PHASE III EVIDENCE SHOWS SIGNIFICANT IMPROVEMENTS WITH ERBITUX® IN COMBINATION WITH FOLFOX VERSUS FOLFOX ALONE IN RESPONSE RATE, DISEASE PROGRESSION AND SURVIVAL.APPROVAL BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION (NMPA) OF CHINA FOR THE FIRST-LINE TREATMENT FOR PATIENTS WITH RAS WILD-TYPE (WT) METASTATIC COLORECTAL CANCER (MCRC) IN COMBINATION WITH FOLFOX OR FOLFIRI, OR IN COMBINATION WITH IRINOTECAN IN PATIENTS WHO ARE REFRACTORY TO IRINOTECAN-BASED CHEMOTHERAPY.  Full Article

German stocks - Factors to watch on November 20

BERLIN/FRANKFURT, Nov 20 The following are some of the factors that may move German stocks on Wednesday: